Altimmune Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2834 https://altimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune Inc

Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors - Mar 27th, 2023 8:05 pm
Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial - Mar 21st, 2023 11:00 am
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update - Feb 28th, 2023 12:00 pm
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 - Feb 21st, 2023 12:30 pm
Altimmune Appoints Raymond Jordt as Chief Business Officer - Jan 4th, 2023 12:30 pm
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023 - Jan 4th, 2023 12:30 pm
Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) - Dec 20th, 2022 12:00 pm
Altimmune to Participate at Two Upcoming Investor Conferences - Nov 22nd, 2022 12:30 pm
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update - Nov 10th, 2022 12:00 pm
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10 - Nov 3rd, 2022 11:30 am
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting® - Oct 28th, 2022 11:30 am
Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight - Sep 28th, 2022 11:30 am
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD - Sep 14th, 2022 11:00 am
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update - Aug 11th, 2022 11:00 am
Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11 - Aug 4th, 2022 11:30 am
Will Altimmune (NASDAQ:ALT) Spend Its Cash Wisely? - Jul 7th, 2022 12:17 pm
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022 - Jun 17th, 2022 11:30 am
Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet - Jun 8th, 2022 1:55 pm
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022 - May 31st, 2022 11:30 am
Insider Buying: The Altimmune, Inc. (NASDAQ:ALT) Independent Director Just Bought 6.6% More Shares - May 31st, 2022 10:08 am